Trial Profile
Efficacy and Safety of Symbicort Turbuhaler 160/4.5 microg/Inhalation, Two Inhalations Twice Daily Plus as-Needed Compared With Seretide Diskus 50/500 microg/Inhalation, One Inhalation Twice Daily Plus Terbutaline Turbuhaler 0.4 mg/Inhalation as-Needed - a 6-Month, Randomised, Double-Blind, Parallel-Group, Active Controlled, Multinational Phase IIIB Study in Adult and Adolescent Patients With Persistent Asthma (AHEAD)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Sep 2021
Price :
$35
*
At a glance
- Drugs Budesonide/formoterol (Primary) ; Salmeterol/fluticasone propionate; Terbutaline
- Indications Asthma
- Focus Therapeutic Use
- Acronyms AHEAD
- Sponsors AstraZeneca
- 19 Nov 2020 Results of economic analysis from three clinical trials: COMPASS, COSMOS and AHEAD presented at the 23rd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
- 01 Jan 2018 Results of pooled post-hoc analysis from six studies (STEAM, STEP, STAY, SMILE, COMPASS and AHEAD) published in the European Respiratory Journal.
- 22 Nov 2005 New trial record.